ClariVest Asset Management’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

ClariVest Asset Management’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-20,900	Closed	-$494K	–	750
2019 Q3	$494K	Sell	20,900 -200	-0.9%	-$5.93K	0.01%	412
2019 Q2	$635K	Sell	21,100 -200	-0.9%	-$4.58K	0.01%	343
2019 Q1	$477K	Buy	21,300 +1,200	+6%	+$25.8K	0.01%	462
2018 Q4	$366K	Buy	+20,100	New	+$316K	0.01%	482

Other funds holding RARX

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClariVest Asset Management's RARX Position: Q4 2019 in Review

ClariVest Asset Management sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q4 2019, closing a stake of 20,900 shares — an estimated $494K sold.

ClariVest Asset Management first reported a position in RARX in Q4 2018 and held it in 4 quarters. The position peaked at $635K in Q2 2019. 146 funds tracked by Wall St. Rank hold RARX as of Q4 2019.

ClariVest Asset Management reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
ClariVest Asset Management sold 20,900 Ra Pharmaceuticals, Inc. Common Stock shares in Q4 2019, an estimated $494K.
ClariVest Asset Management first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2018 and held it in 4 quarters.
ClariVest Asset Management's Ra Pharmaceuticals, Inc. Common Stock position peaked at $635K in Q2 2019.
146 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q4 2019.

Based on ClariVest Asset Management's 13F filing for Q4 2019, filed 12 Feb 2020.